Mirvetuximab soravtansine-gynx compared to chemotherapy in folate receptor alpha-positive platinum resistant ovarian cancer led to improved survival
1. Mirvetuximab soravtansine-gynx (MIRV), significantly improved progression-free survival, objective response, and overall survival compared to chemotherapy in patients with platinum-resistant, ...
